MENU

Targeted RNA-Sequencing Detects Fusion Gene Signature in Rare Form of Lung Cancer

April 29, 2019

“This finding could be used for diagnostic tools and potential targeted therapy,” said Shuanzeng Wei MD, PhD, corresponding author of the study. “This finding could be used for diagnostic tools and potential targeted therapy,” said Shuanzeng Wei MD, PhD, corresponding author of the study.

PHILADELPHIA (April 29, 2019) — Using next-generation sequencing (NGS) based RNA-sequencing, researchers at Fox Chase Cancer Center found a fusion gene signature in primary tracheobronchial adenoid cystic carcinoma, a rare lung tumor. This study is the first time the MYB/MYBL1 fusion genes have been systemically investigated for this cancer type.

The researchers studied seven specimens of the carcinoma, and detected fusions of either MYB or MYBL1 genes in all seven. Three cases had MYB-NFIB, and three had MYBL1-NFIB. The remaining case showed a rare MYBL1-RAD51B fusion, which had never been reported in tracheobronchial adenoid cystic carcinoma. These findings suggest that rearrangement involving MYB or MYBL1 is a hallmark of tracheobronchial adenoid cystic carcinoma.

“This finding could be used for diagnostic tools and potential targeted therapy,” said Shuanzeng Wei MD, PhD, assistant professor of pathology at Fox Chase, corresponding author of the study. The publication appears in Modern Pathology, which is the official journal of the United States & Canadian Academy of Pathology (USCAP).

“NGS RNA-sequencing is a powerful approach for identifying translocation/rearrangement of solid tumors or hematological malignancies. The targeted RNA fusion panel used in this study consists of 507 well-known cancer-related fusion genes, which covers 7690 exotic regions that are targeted with a total of 21,283 probes,” said Jianming Pei, MD, assistant research professor of cancer biology at Fox Chase, the first author of the study.

This targeted RNA fusion NGS panel is in its development stage for clinical use and will be provided for the clinicians soon.

This study is a collaboration between the Fox Chase Genomics Facility and Department of Pathology. Other authors include Joseph R. Testa, PhD and Jacqueline N. Talarchek from the Cancer Biology Program, and members from Pathology: Douglas B. Flieder, MD, Arthur S. Patchefsky, MD, and Harry S. Cooper, MD. The study is supported by NCI grant P30 CA006927 (FCCC Comprehensive Cancer Center Core Grant).

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase